Immunomodulation and Patients` Outcomes Following Treatment of Hepatocellular Carcinoma by Radiofrequency Ablation, Microwave Ablation, Trans-Arterial Chemoembolization or Radio-embolization


About this study

The goal of the study is to identify immune responses (immune cell activation and suppression) following local ablation of liver tumors.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Patients 18-100 years of age
  2. Hepatocellular carcinoma diagnosed by biopsy or non-invasive criteria..
  3. Amenable to radiofrequency , microwave ablations or trans-catheter arterial chemoembolization or radioembolization
  4. Able to undergo blood draws
  5. Willing to return to Rochester for 3 month follow-up
  6. Provision of informed consent

Exclusion Criteria:

  1. Age <18 years
  2. Multicentric HCC (beyond size and number allowed for inclusion)
  3. Lymphovascular or adjacent organ spread
  4. Distant metastasis
  5. Unfit for loco-regional ablation for any other reason

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lewis Roberts, M.B., Ch.B., Ph.D.

Open for enrollment

Contact information:

Nasra Giama D.N.P., R.N.


More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions